GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » 14-Day RSI

Gentian Diagnostics AS (OSL:GENT) 14-Day RSI : 49.84 (As of Mar. 13, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-03-13), Gentian Diagnostics AS's 14-Day RSI is 49.84.

The industry rank for Gentian Diagnostics AS's 14-Day RSI or its related term are showing as below:

OSL:GENT's 14-Day RSI is ranked worse than
65.13% of 889 companies
in the Medical Devices & Instruments industry
Industry Median: 44.39 vs OSL:GENT: 49.84

Competitive Comparison of Gentian Diagnostics AS's 14-Day RSI

For the Medical Devices subindustry, Gentian Diagnostics AS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS's 14-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's 14-Day RSI falls into.



Gentian Diagnostics AS  (OSL:GENT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gentian Diagnostics AS  (OSL:GENT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Gentian Diagnostics AS 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Gentian Diagnostics AS Business Description

Traded in Other Exchanges
N/A
Address
Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Gentian Diagnostics AS Headlines